Ling Pan

机构：Tianjin University of Science and Technology, Chinese Academy of Medical Sciences & Peking Union Medical College, Sichuan University, West China Hospital of Sichuan University, National Clinical Research, Institute of Hematology & Blood Diseases Hospital

发表论文 18 篇 · 总被引 28 次 · h-index 3

代表论文

• A predictive model for therapy failure in patients with chronic myeloid leukemia receiving tyrosine kinase inhibitor therapy (2024 · Blood · 被引 9)
• Improved efficacy and safety of zanubrutinib versus ibrutinib in patients with relapsed/refractory chronic lymphocytic leukemia (R/R CLL) in China: a subgroup of ALPINE (2024 · Annals of Hematology · 被引 8)
• A predictive risk‐scoring model for survival prognosis of multiple myeloma based on gain/amplification of 1q21: Experience in a tertiary hospital in South‐Western China (2024 · Cancer Medicine · 被引 3)
• The impact of letermovir prophylaxis in matched sibling donor haematopoietic stem cell transplantation: Selecting the appropriate population for optimal prophylactic therapy (2025 · British Journal of Haematology · 被引 2)
• Incidence, Risk Factors, and Outcomes of Bloodstream Infection during Conditioning Phase before Allogeneic Hematopoietic Stem Cell Transplantation (2025 · Transplantation and Cellular Therapy · 被引 2)
• [Relationship between VEGF and MMP-2, MMP-9 in 82 patients with acute myeloid leukemia]. (2006 · PubMed · 被引 2)